Kintara Therapeutics Inc. and TuHURA Biosciences Inc. announced that they have entered into a definitive agreement for an all-stock transaction forming a company with expertise and resources to advance a risk-diversified late-stage oncology pipeline.
Tag Archive for: merger
Sun Pharma first moved to acquire Taro in May 2007, at the time offering $454 million or $7.75 per share.
The acquisition announced on Friday will give Bristol Myers Squibb ownership of Karuna Therapeutics’ investigational antipsychotic KarXT, which is being tested for schizophrenia and Alzheimer’s disease psychosis.
“Separately, Wunderman Thompson and VMLY&R are two of WPP’s strongest and best-performing agencies. Together, they will deliver an even wider, fully integrated suite of capabilities to our clients in every market. Marketers today expect seamless links between their brand advertising and technology solutions and platforms,” said WPP CEO Mark Read. “VML provides an immediate solution to this business imperative.”
Bristol Myers Squibb on Sunday announced that it has entered into a definitive merger agreement with cancer-focused biotech Mirati Therapeutics in a bid to grow its oncology franchise.
The case will be “withdrawn from adjudication” until Sept. 18, according to the filing, and this will allow the FTC to consider other avenues of resolving the matter, including a settlement.
The companies have filed their own suit against the Federal Trade Commission, claiming the FTC’s attempt to legally block their $28 billion merger is unconstitutional.
The buyout will grant Leap Therapeutics access to Flame Bioscience’s portfolio, which includes a clinical-stage monoclonal antibody that is under investigation as a potential treatment for gastric, gastroesophageal junction, and pancreatic cancers.
In addition to becoming a Nasdaq-listed company, the focus of Elicio moving forward will be a therapeutic cancer vaccine candidate that targets mKRAS-driven tumors.
U.S. life sciences company Illumina on Tuesday challenged an EU antitrust order to keep biotech firm Grail separate, ratcheting up its fight against EU regulators which blocked a merger deal last year.
